Her-2/neu and topoisomerase IIα in advanced breast cancer: A comprehensive FISH analysis of 245 cases

Diagnostic Molecular Pathology

Volumn 21, Issue 2, 2012, Pages 77-83

  Engelstaedter, Verena ^a   Schiffers, Jennifer ^b   Kahlert, Steffen ^c   Mainka, Patrick ^d   Engel, Jutta ^a   Kirchner, Thomas ^b   Diebold, Joachim ^e   Mayr, Doris ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b Institute of Pathology   (Germany)

^c Campus Großhadern ^*  (Germany)

^d Klinikum Harlaching   (Germany)

^e Pathologische Institut am Kantonsspital Luzern   (Switzerland)

Author keywords

advanced breast cancer; coamplification; FISH; Her 2 neu; prognosis; topoisomerase IIa

Indexed keywords

DNA TOPOISOMERASE; DNA TOPOISOMERASE IIALPHA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DELETION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; DNA COPY NUMBER VARIATIONS; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; FEMALE; GENE AMPLIFICATION; GENETIC ASSOCIATION STUDIES; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 84861231703     PISSN: 10529551     EISSN: 15334066     Source Type: Journal    
DOI: 10.1097/PDM.0b013e31823b6e43     Document Type: Article

References (26)

1. Kreienberg R, Kopp I, Albert U, et al. Interdisciplinary S3 guidelines for the diagnostic, therapy, and aftercare of breast cancer. München, Germany: W. Zuckschwerdt Verlag GmbH; 2008.
2. World Health Organization (WHO). Classification of tumours Pathology and genetics: Tumours of the breast and female genital organs. Lyon: IARC Press; 2003.
3. Pegram MD, Pauletti G, Slamon DJ. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat. 1998;52:65-77. (Pubitemid 29056086)
4. Gasparini G, Longo R, Torino F, et al. Therapy of breast cancer with molecular targeting agents. Ann Oncol. 2005;16(suppl 4): iv28-iv36. (Pubitemid 43084943)
5. Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol. 1992;10: 1049-1056.
6. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792. (Pubitemid 32222155)
7. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659-1672. (Pubitemid 41464705)
8. Dahabreh IJ, Linardou H, Siannis F, et al. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist. 2008;13:620-630. (Pubitemid 351904907)
9. Koren R, Rath-Wolfson L, Ram E, et al. Prognostic value of topoisomerase II in female breast cancer. Oncol Rep. 2004;12: 915-919.
10. Kalogeraki A, Ieromonachou P, Kafousi M, et al. Topoisomerase II alpha expression in breast ductal invasive carcinomas and correlation with clinicopathological variables. In Vivo. 2005;19:837-840. (Pubitemid 41065141)
11. Depowski PL, Rosenthal SI, Brien TP, et al. Topoisomerase II expression in breast cancer: correlation with outcome variables. Mod Pathol. 2000;13:542-547. (Pubitemid 30332106)
12. Gennari A, Prozanto P. New understanding of the role of anthracyclines in early-stage breast cancer: patient selection considerations. Clin Breast Cancer. 2008;8:179-183.
13. Zhu L, Li YF, Chen WG, et al. HER2 and topoisomerase II alpha: possible predictors of response to neoadjuvant chemotherapy for breast cancer patients. Chin Med J (Engl). 2008;121:1965-1968.
14. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131:18-43. (Pubitemid 46174133)
15. Pauletti G, Dandekar S, Rong H, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000;18:3651-3664.
16. Hicks DG, Yoder BJ, Pettay J, et al. The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 geneamplification: a fluorescence in situ hybridization study. Hum Pathol. 2005;36:348-356. (Pubitemid 40591804)
17. Beser AR, Tuzlali S, Guzey D, et al. HER-2, TOP2A and chromosome 17 alterations in breast cancer. Pathol Oncol Res. 2007;13:180-185. (Pubitemid 350221219)
18. Mano MS, Rosa DD, De Azambuja E, et al. The 17q12-q21 amplicon: Her2 and topoisomerase-II alpha and their importance to the biology of solid tumours. Cancer Treat Rev. 2007;33:64-77. Epub 2006 Nov 17. (Pubitemid 46132005)
19. Di Leo A, Gancberg D, Larsimont D, et al. HER-2 amplification and topoisomerase II alpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res. 2002;8:1107-1116. (Pubitemid 34517647)
20. Schindlbeck C, Janni W, Shabani M, et al. Isolated tumor cells in the bone marrow (ITC-BM) of breast cancer patients before and after anthracyclin based therapy: influenced by the HER2- and Topoisomerase II alpha-status of the primary tumor? J Cancer Res Clin Oncol. 2005;131:539-546. (Pubitemid 41215309)
21. Fritz P, Cabrera CM, Dippon J, et al. c-erbB2 and topoisomerase II alpha protein expression independently predict poor survival in primary human breast cancer: a retrospective study. Breast ancer Res. 2005;7:R374-R384.
22. ÓMalley FP, Chia S, Tu D, et al. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst. 2009;101:644-650.
23. Schindlbeck C, Mayr D, Olivier C, et al. Topoisomerase IIa expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer. J Cancer Res Clin Oncol. 2010;136:1029-1037.
24. Arriola E, Rodriguez-Pinilla SM, Lambros MB, et al. Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Res Treat. 2007;106:181-189. (Pubitemid 350045015)
25. Nielsen KV, Ejlertsen B, Mller S, et al. The value of TOP2A gene copy number variation as a biomarker in breast cancer: update of DBCG trial 89D. Acta Oncol. 2008;47:725-734. (Pubitemid 351878451)
26. Nielson KV, Müller S, Moller S, et al. Aberrations of ERBB2 and TOP2A genes in breast cancer. Mol Oncol. 2010;4:161-168